Our objective was to evaluate whether cannabis use was associated with nausea and vomiting in early pregnancy. Participants from nuMoM2b (Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be) enrolled from October 2010 through September 2013 with a PUQE (Pregnancy-Unique Quantification of Emesis) questionnaire and an available stored urine sample from the first study visit (median gestational age 12 weeks) were included. Cannabis exposure was ascertained by urine immunoassay for 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH); positive results were confirmed with liquid chromatography tandem mass spectrometry. The primary outcome was moderate-to-severe nausea by the PUQE score. Overall, 9,250 participants were included, and 5.8% (95% CI 5.4–6.3%) had detectable urine THC-COOH. In adjusted analyses, higher THC-COOH levels were associated with greater odds of moderate-to-severe nausea (20.7% in the group with THC-COOH detected vs 15.5% in the group with THC-COOH not detected, adjusted odds ratio 1.6, 95% CI 1.1–2.2 for a 500 ng/mg Cr THC-COOH increment).

我们的目的是评估大麻的使用是否与怀孕早期的恶心和呕吐有关。nuMoM2b（未生育妊娠结果研究：监测准妈妈）的参与者于 2010 年 10 月至 2013 年 9 月期间登记，并填写了 PUQE（妊娠唯一呕吐定量）调查问卷和第一次研究访视时储存的可用尿液样本（中位孕龄） 12 周）也包括在内。通过尿液免疫测定 11-正-9-羧基-δ-9-四氢大麻酚 (THC-COOH) 确定大麻暴露；液相色谱串联质谱法证实了阳性结果。主要结局是 PUQE 评分显示的中度至重度恶心。总体而言，纳入了 9,250 名参与者，其中 5.8% (95% CI 5.4–6.3%) 的尿液中可检测到 THC-COOH。在调整后的分析中，较高的 THC-COOH 水平与较高的中度至重度恶心几率相关（检测到 THC-COOH 的组为 20.7%，未检测到 THC-COOH 的组为 15.5%，调整后的比值比为 1.6，对于 500 ng/mg Cr THC-COOH 增量，95% CI 1.1–2.2）。